AbbVie combines advanced science, expertise and passion to solve serious health issues and have a remarkable impact on people’s lives. Read through our press releases to see our latest efforts to improve patient care.

If you are a member of the news media and have questions or need additional information, please contact our Communications Team.

Mar 28, 2017

AbbVie and M2Gen Announce New Collaboration for the Oncology Research Information Exchange Network® (ORIEN) Avatar Research Program

NORTH CHICAGO, Ill. and TAMPA, Fla., March 28, 2017 /PRNewswire/ -- AbbVie, a global biopharmaceutical company, and M2Gen, a leading health informatics solutions company, announced today that AbbVie has joined the Oncology Research Information Exchange Network® (ORIEN) Avatar Research Program. Launched in April of 2016, the ORIEN Avatar Research Program fosters collaboration among key stakeholders in cancer research with the shared goal of discovering and developing novel therapies in clinical trials.   

Mar 23, 2017

Julianne Hough Empowers Women to "Get in the Know" About Endometriosis

NORTH CHICAGO, Ill., March 23, 2017 /PRNewswire/ -- AbbVie, a global biopharmaceutical company, today announced that actress, dancer and Emmy Award-winning choreographer Julianne Hough is helping to raise awareness about endometriosis through a campaign called "Get in the Know about ME in EndoMEtriosis." The campaign, sponsored by AbbVie, is dedicated to inspiring women to learn about and understand endometriosis, a disease affecting an estimated one in 10 women,1 and to address their symptoms with a healthcare professional.  Despite being one of the most common gynecologic disorders in America, there is a lack of awareness and prioritization of endometriosis as an important women's health issue.

Mar 14, 2017

AbbVie Granted Priority Review in Japan for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C

NORTH CHICAGO, Ill., March 14, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that priority review has been granted by the Japanese Ministry of Health, Labour and Welfare (MHLW) for its investigational, pan-genotypic, ribavirin-free regimen of glecaprevir/pibrentasvir (G/P) for the treatment of all major genotypes (GT1-6) of the chronic hepatitis C virus (HCV). This priority review follows European Medicines Agency (EMA) accelerated assessment and U.S. Food and Drug Administration (FDA) priority review designations in December 2016 and January 2017 respectively.

Mar 01, 2017

AbbVie to Present at the Barclays Global Healthcare Conference

NORTH CHICAGO, Ill., March 1, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Barclays Global Healthcare Conference on Wednesday, March 15, 2017. William Chase, executive vice president and chief financial officer, will present at 8 a.m. Central time.

Feb 27, 2017

AbbVie Receives CHMP Positive Opinion for Eight-Week Treatment Option with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for Patients with Genotype 1b Chronic Hepatitis C

NORTH CHICAGO, Ill., Feb. 27, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion for a shorter, eight-week treatment of VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) as an option for previously untreated adult patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) and minimal to moderate fibrosis*.

Feb 17, 2017

AbbVie Announces $5 Billion Increase to Stock Repurchase Program

NORTH CHICAGO, Ill., Feb. 17, 2017 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) has authorized a $5 billion increase to AbbVie's existing stock repurchase program.

Feb 16, 2017

AbbVie Declares Quarterly Dividend

NORTH CHICAGO, Ill., Feb. 16, 2017 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.64 per share. 

Feb 15, 2017

AbbVie to Present at the Cowen and Company 37th Annual Health Care Conference

NORTH CHICAGO, Ill., Feb. 15, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Cowen and Company 37th Annual Health Care Conference on Wednesday, March 8, 2017. William Chase, executive vice president and chief financial officer, will present at 8:20 a.m. Central time.

Feb 02, 2017

U.S. FDA Grants Priority Review to AbbVie for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)

NORTH CHICAGO, Ill., Feb. 2, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) and granted priority review for its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P), being evaluated for the treatment of all major genotypes (GT1-6) of chronic hepatitis C virus (HCV). The FDA grants priority review designation to medicines that it determines have the potential to provide significant improvements in the safety and effectiveness of the treatment of a serious disease. The NDA is supported by data from eight registrational studies in AbbVie's G/P clinical development program, which evaluated more than 2,300 patients in 27 countries across all major HCV genotypes and for special populations.

Jan 27, 2017

AbbVie Reports Full-Year and Fourth-Quarter 2016 Financial Results

NORTH CHICAGO, Ill., Jan. 27, 2017 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the fourth quarter and full year ended December 31, 2016.